Food, drug, insect sting allergy, and anaphylaxis
The role of penicillin in benign skin rashes in childhood: A prospective study based on drug rechallenge

https://doi.org/10.1016/j.jaci.2010.08.025Get rights and content

Background

Delayed-onset urticarial or maculopapular rashes are frequently observed in children treated with β-lactams. Many are labeled “allergic” without reliable testing.

Objective

Determine the etiology of these rashes by exploring both infectious and allergic causes.

Methods

Children presenting to the emergency department with delayed-onset urticarial or maculopapular rashes were enrolled. Acute and convalescent sera were obtained for viral screening along with a throat swab. Subjects underwent intradermal and patch skin testing for β-lactams 2 months after presentation. Anti–β-lactam blood allergy tests were also obtained. All subjects underwent an oral challenge test (OCT) with the culprit antibiotic.

Results

Eighty-eight children were enrolled between 2006 and 2008. There were 11 (12.5%) positive intradermal and no positive patch tests. There were 2 (2.3%) positive blood allergy tests. There were 6 (6.8%) subjects with a positive OCT, 2 were intradermal-negative, and 4 were intradermal-positive. No OCT reactions were more severe than the index event. Most subjects had at least 1 positive viral study, 54 (65.9%) in the OCT negative group.

Conclusion

In this situation, β-lactam allergy is clearly overdiagnosed because the skin rash is only rarely reproducible (6.8%) by a subsequent challenge. Viral infections may be an important factor in many of these rashes. OCTs were positive in a minority of intradermal skin test–positive subjects. Patch testing and blood allergy testing provided no useful information. OCTs should be considered in all children who develop a delayed-onset urticarial or maculopapular rash during treatment with a β-lactam.

Key words

Drug allergy
virus
skin rash
children
penicillin
β-lactam
cephalosporin
oral challenge
skin test
blood allergy test

Abbreviations used

CMV
Cytomegalovirus
EBV
Epstein-Barr virus
HHV6
Human herpes virus 6
MDM
Minor determinant mixture
OCT
Oral challenge test
PPL
Penicilloyl-polylysine

Cited by (0)

Supported by a Geneva University Hospitals Research & Development Award #06-I-7 and in part by a Swiss National Foundation research grant (3200B-101670).

Disclosure of potential conflict of interest: L. Kaiser has received research support from the Swiss National Foundation. P. A. Eigenmann has received speakers' honoraria from Phadia. The rest of the authors have declared that they have no conflict of interest.

View Abstract